UBS Group Downgrades Demant A/S (OTCMKTS:WILYY) to Hold

Demant A/S (OTCMKTS:WILYY) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts have also weighed in on WILYY. Sanford C. Bernstein lowered shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Zacks Research upgraded shares of Demant A/S to a “hold” rating in a research note on Friday, June 26th. Finally, Morgan Stanley upgraded shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Demant A/S currently has a consensus rating of “Moderate Buy”.

Demant A/S Price Performance

Demant A/S stock opened at $20.66 on Wednesday. The company’s fifty day simple moving average is $19.64 and its 200-day simple moving average is $16.98. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36. Demant A/S has a 12 month low of $13.45 and a 12 month high of $20.98.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.